The American pharmaceutical giant Eli Lilly and Co. is encroaching on Novo Nordisk’s territory. However, Novo Nordisk, the pioneer behind Ozempic, is now working to regain its lead. More details are emerging about the drugs Novo Nordisk wants to use to replace its flagship treatments, Ozempic and Wegovy, both based on semaglutide. Last week, Novo Nordisk announced the launch of Phase 3 trials for amicretin, a compound designed to build on semaglutide’s legacy. Surprisingly, Novo Nordisk Has Chosen Not to